Iontophoresis dosing device

Abstract

The invention belongs to the technical field of medical auxiliary instruments, and relates to an iontophoresis dosing device which comprises a ring body, the ring body comprises a first shell, a second shell and two connecting pieces of the same structure, and the two connecting pieces are located on the two sides of the first shell correspondingly to achieve connection of the first shell and the second shell; the first treatment assembly comprises a first hydrogel patch, a second hydrogel patch and a constant current source circuit system, the first hydrogel patch is arranged on the concave surface of the first shell, the second hydrogel patch is arranged on the concave surface of the second shell, and the constant current source circuit system is arranged on the second shell and electrically connected with the first hydrogel patch and the second hydrogel patch; an electric field perpendicular to eyes is formed, so that gaps of cornea and sclera are changed to form a water channel with a fixed direction, and medicine enters the deep positions of the eyes along the water channel. The device is small in size, convenient to operate, capable of being used at home and low in economic cost, and the transdermal drug delivery efficiency and stability are improved.

Description

Technical Field

[0001] The invention belongs to the technical field of medical auxiliary equipment, and in particular relates to an iontophoresis drug delivery device. Background Art

[0002] With the development of society and the improvement of medical level, people pay more and more attention to the treatment of eye diseases. Due to the special anatomical structure and physiological barriers of the eyeball, the delivery of drugs to the target site faces great challenges. Topical administration is a safe and convenient method, mainly in the form of eye drops, which are often used to treat anterior segment diseases. However, due to tear drainage, aqueous humor circulation and blood-eye barrier, the amount of eye drops that penetrate into the anterior segment of the eye is less than 5%, and it is difficult to reach the posterior segment of the eye under the further obstruction of the iris lens. Invasive treatment is the most common method to increase the concentration of drugs in the eye, but this method of administration is prone to cause intraocular infection and tissue damage, and the patient's compliance is poor, resulting in poor efficacy. Therefore, the use of non-invasive methods to prolong the drug residence time and enhance the permeability of drugs is the main goal of the current treatment of eye diseases.

[0003] The non-invasive device currently used in clinical practice to prolong drug residence time and enhance drug permeability is ultrasonic conductance. Its main structure includes a controller, an ultrasonic drug permeation instrument, an ultrasonic generator, a transducer, a treatment head, a display, an operation panel, a power module, a cooling system, and a communication interface. The main structure is complex and large in size. Before using the device, the ultrasonic drug permeation instrument needs to be connected to the medicine bottle or injection needle to ensure a firm connection to prevent leakage of the drug solution. Then, the injection mode and speed of the ultrasonic drug permeation instrument are adjusted as needed. According to the doctor's instructions or the instructions for use of the drug, set the appropriate injection volume and rate, and then place the ultrasonic drug permeation instrument on the site where the drug needs to be injected. After using ultrasound to accurately locate, press the injection button on the ultrasonic drug permeation instrument to start injecting the drug. At the same time, use the ultrasound instrument to monitor the distribution of the drug solution during the injection process so that the drug is delivered to the target area according to the predetermined path and speed.

[0004] With the advancement of social science and technology and the improvement of the overall economic level of society, home health care has attracted widespread attention. However, the equipment currently used in clinical practice is large in size and requires professional medical technicians to operate it because it requires ultrasound guidance. It can only be used in hospitals and is difficult to be used in home medical care. Patients' long-term intermittent visits to the hospital will increase their psychological and economic burdens. Summary of the invention

[0005] In view of this, the present invention provides an iontophoresis drug delivery device, which is small in size, wearable in design and convenient to operate, so that it can be used at home, has high transdermal drug delivery efficiency and stability, reduces the economic cost of patients' long-term intermittent visits to the hospital, and solves the above-mentioned technical problems.

[0006] The technical solution of the present invention is:

[0007] An iontophoresis drug delivery device, comprising:

[0008] A ring body, used to be worn on the patient's head, the ring body comprising a first shell, a second shell and two connecting pieces with the same structure, the first shell and the second shell having opposite sides arranged in an arc shape, the two connecting pieces are respectively located on both sides of the first shell, and are used to realize the connection between the first shell and the second shell;

[0009] A first treatment component, comprising a first hydrogel patch, a second hydrogel patch and a constant current source circuit system, wherein the first hydrogel patch is arranged on the concave surface of the first shell and is used to be placed on the eye, the second hydrogel patch is arranged on the concave surface of the second shell and is used to be placed on the back of the head, and the constant current source circuit system is arranged on the second shell and is electrically connected to the first hydrogel patch and the second hydrogel patch respectively;

[0010] When the constant current source circuit system supplies power to the first hydrogel patch and the second hydrogel patch, an electric field perpendicular to the eye is formed between the first hydrogel patch and the second hydrogel patch. Under the action of the electric field, the gap between the cornea and sclera changes to form a water channel with a fixed direction, and the drug enters deep into the eye along the water channel.

[0011] Furthermore, the first hydrogel patch includes a first conductive hydrogel and a first electrode sheet arranged in a stacked structure, the first electrode sheet is arranged on the concave surface of the first shell and is electrically connected to the constant current source circuit system; the first electrode sheet includes a first flexible substrate, a first wire and a first electrode, the first wire and the first electrode are printed on the first flexible substrate, the two ends of the first wire are electrically connected to the first electrode and the constant current source circuit system respectively, and a first 3M double-sided tape is provided on one side of the first flexible substrate, and the first 3M double-sided tape is used to achieve connection with the first shell.

[0012] Furthermore, the second hydrogel patch includes a second conductive hydrogel arranged in a stacked structure and a second electrode sheet arranged in a stacked structure, the second electrode sheet is tightly attached to the concave surface of the second shell and is electrically connected to the constant current source circuit system; the second electrode sheet includes a second flexible substrate, a second wire and a second electrode sheet, the second wire and the second electrode sheet are printed on the second flexible substrate, the two ends of the second wire are electrically connected to the second electrode sheet and the constant current source circuit system respectively, and a second 3M double-sided tape is provided on one side of the second flexible substrate, and the second 3M double-sided tape is used to achieve connection with the second shell.

[0013] Furthermore, the first electrode sheet and the second electrode sheet are square, with a side length of 1 cm to 2 cm.

[0014] Furthermore, the first conductive hydrogel and the second conductive hydrogel are rectangles of 3 cm×15 cm.

[0015] Furthermore, the first shell is replaced by a third shell, and the second treatment component is arranged on the third shell and the second shell. The third shell includes a frame and a lens arranged on the frame, and a third hydrogel patch is arranged on the side of the frame close to the second shell. The third hydrogel patch is frame-shaped, and its structure matches the frame; the constant current source circuit system is electrically connected to the third hydrogel patch and the second hydrogel patch respectively. When the constant current source circuit system supplies power to the third hydrogel patch and the second hydrogel patch, an electric field perpendicular to the eye is formed between the third hydrogel patch and the second hydrogel patch. Under the action of the electric field, the gap between the cornea and sclera changes to form a water channel with a fixed direction, and the drug enters the deep part of the eye along the water channel.

[0016] Furthermore, the third hydrogel patch includes a third conductive hydrogel and a third electrode sheet, the third conductive hydrogel and the third electrode sheet are composed of a stacked structure, the third electrode sheet is arranged on the frame and is frame-shaped, the third electrode sheet includes a third flexible substrate, a third wire and a third electrode sheet, the third flexible substrate is printed with a third wire and a third electrode sheet, the two ends of the third wire are respectively electrically connected to the third electrode sheet and the positive interface terminal of the constant current source circuit system, and a third 3M double-sided tape is arranged on one side of the third flexible substrate, and the third 3M double-sided tape is used to achieve connection with the frame.

[0017] Furthermore, the second treatment component also includes: a nebulizer catheter interface, a nebulizer and a nebulizer catheter, the nebulizer catheter interface is opened on the third shell and passes through the concave surface of the third shell, one end of the nebulizer catheter is detachably connected to the nebulizer catheter interface, and the other end of the nebulizer catheter is detachably connected to the nebulizer.

[0018] Compared with the prior art, the iontophoresis drug delivery device provided by the present invention is worn on the patient's head by a ring body to fix the device, and the first hydrogel patch, the second hydrogel patch and the constant current source circuit system on the ring body structure work together. The constant current source circuit system generates a constant current field to act on the first hydrogel patch and the second hydrogel patch, thereby generating a directional electric field between the first hydrogel patch and the second hydrogel patch, increasing the corneal scleral gap through electric field stimulation, guiding the drug to be transported in a directional depth along the direction of the electric field, and improving the drug delivery efficiency and accuracy. The device is easy to operate and can improve the efficiency and stability of transdermal drug delivery. The entire device is small in size, and the wearable design and convenient operation make it possible to use it at home, reducing the economic cost of patients' long-term intermittent visits to the hospital. It can be widely used in eye treatment, has strong practicality, and is worth promoting. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 It is a structural diagram of the first embodiment of the present invention.

[0020] Figure 2 It is a structural diagram of a second embodiment of the present invention.

[0021] Figure 3 The structure of the first hydrogel patch of the present invention is shown in FIG. Figure 1 .

[0022] Figure 4 The structure of the first hydrogel patch of the present invention is shown in FIG. Figure 2 .

[0023] Figure 5 It is a schematic structural diagram of the first electrode sheet of the present invention.

[0024] Figure 6 The structure of the second hydrogel patch of the present invention is shown in FIG. Figure 1 .

[0025] Figure 7 The structure of the second hydrogel patch of the present invention is shown in FIG. Figure 2 .

[0026] Figure 8 It is a schematic structural diagram of the second electrode sheet of the present invention. DETAILED DESCRIPTION

[0027] The equipment currently used in clinical practice is large in size, and because it requires ultrasound guidance during operation, it requires professional medical technicians to operate it. It can only be used in hospitals and is difficult to be used in home medical care. Long-term intermittent visits to the hospital for treatment will increase the psychological and financial burden on patients.

[0028] In order to solve the above-mentioned technical problems, the technical solution of this application is specially designed.

[0029] In order to enable those skilled in the art to better understand and implement the technical solution of the present invention, the present invention is further described below in conjunction with specific embodiments and drawings.

[0030] In the description of the present invention, it should be understood that the terms "center", "longitudinal", "lateral", "length", "width", "thickness", "up", "down", "front", "back", "left", "right", "vertical", "horizontal", "top", "bottom", "inside", "outside", "clockwise", "counterclockwise", "axial", "radial", "circumferential" and the like indicate positions or positional relationships based on the positions or positional relationships shown in the accompanying drawings, and are only for the convenience of describing the present invention and simplifying the description, rather than indicating or implying that the device or element referred to must have a specific orientation, be constructed and operated in a specific orientation, and therefore cannot be understood as limiting the present invention. The terms "first" and "second" are used for descriptive purposes only, and cannot be understood as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Therefore, the features defined as "first" and "second" may explicitly or implicitly include one or more of the features, and in the description of the present invention, unless otherwise specified, "multiple" means two or more.

[0031] The present invention provides an iontophoresis drug delivery device, Figures 1 to 8 The present invention is described with reference to the structural schematic diagram of FIG.

[0032] Example 1

[0033] like Figure 1 As shown, the present invention provides an iontophoresis drug delivery device, the main structure of which includes a first shell 1, a second shell 2 and two connectors 3 of the same structure, the two connectors 3 are respectively located on both sides of the first shell 1, one end of the connector 3 is connected to the first shell 1 through a detachable structure, and the other end of the connector 3 is fixedly connected to the second shell 2, so that the first shell 1 and the second shell 2 form a ring body that is convenient to wear on the patient's head. In use, the first shell 1 is located at the patient's eyes, and the second shell 2 is located at the back of the patient's head. In order to fit the shape of the patient's head and improve the wearing stability, the opposite side of the first shell 1 and the second shell 2 is set to an arc shape.

[0034] In order to meet the needs of different patients, the connecting member 3 can also be set as an elastic structure to adapt to the size of the head, so as to improve the comfort of the patient when wearing it.

[0035] A first treatment component is provided on the first shell 1 and the second shell 2 for realizing the effect of ion electroosmosis drug delivery. When in use, eye drops can be first dripped into the eye, and then the device can be worn with the first shell 1 facing the eye to perform electroosmosis to promote the drug solution to enter the eye.

[0036] The structure of the first treatment component includes a first hydrogel patch 4, a second hydrogel patch 5 and a constant current source circuit system, and its basic principle is based on the basic electrical principle, that is, ions with opposite charges attract each other, and ions with the same charge repel each other. In this embodiment, a constant current source circuit system is used to generate a current field in a constant direction between the first hydrogel patch 4 and the second hydrogel patch 5. The ions and molecules move together in the current field. Due to the adsorption of ions, the liquid is charged as a whole. Under the action of the external electric field, the solution moves in a directional manner, driving the transport of molecules to achieve the movement of the eye drops into the eye.

[0037] Specifically, the power supply current of the constant current source circuit system is in the form of direct current, which is used to stabilize the current size and promote stability during drug administration. Its specific structure includes a power supply, an integrated circuit board, a push button switch and an LED display screen. The power supply, the push button switch and the integrated circuit board are electrically connected in sequence, and the LED display screen and the integrated circuit board are electrically connected.

[0038] Specifically, the constant current source circuit system is arranged on the second shell 2 , which is a hollow shell. The power supply and the integrated circuit board are located inside the hollow shell. The key switch and the LED display are fixedly connected to the second shell 2 and exposed outside the second shell 2 .

[0039] As a further specific implementation scheme of this embodiment, specifically, the power source is a battery with a voltage range of 5V-30V, and the battery can be used continuously for 2 hours when fully charged.

[0040] As a further specific implementation scheme of this embodiment, specifically, the model of the integrated circuit board is SM2018E, and the model of the LED display screen is P6.

[0041] It should be noted that the construction of the constant current source circuit system here is implemented using existing technologies, as long as the basic functions of the device can be achieved. Of course, technicians in this field can also use other system components to replace the given solution to achieve it.

[0042] Specifically, Figure 3 and Figure 4 As shown, the first hydrogel patch 4 is composed of a first conductive hydrogel 41 and a first electrode sheet 42 in a stacked structure, and the first electrode sheet 42 is closely attached to the concave surface of the first shell 1. Specifically, as Figure 5As shown, the first electrode sheet 42 includes a first flexible substrate 421, a first wire 422 and a first electrode 423. The first wire 422 and the first electrode 423 are printed on the first flexible substrate 421. The two ends of the first wire 422 are electrically connected to the first electrode 423 and the constant current source circuit system respectively. A first 3M double-sided tape is provided on one side of the first flexible substrate 421, and the first 3M double-sided tape is used to achieve connection with the first shell 1.

[0043] Specifically, Figure 6 and Figure 7 As shown, the second hydrogel patch 5 is composed of a second conductive hydrogel 51 and a second electrode sheet 52 in a stacked structure, and the second electrode sheet 52 is closely attached to the concave surface of the second housing 2. Figure 8 As shown, the second electrode sheet 52 includes a second flexible substrate 521, a second electrode sheet 522 and a second wire 523, the second flexible substrate 521 is printed with the second electrode sheet 522 and the second wire 523, the two ends of the second wire 523 are electrically connected to the second electrode sheet 522 and the constant current source circuit system respectively, and a second 3M double-sided tape is provided on one side of the second flexible substrate 521, and the second 3M double-sided tape is used to achieve connection with the second shell 2.

[0044] As a further specific implementation of this embodiment, specifically, the thickness of the first 3M double-sided tape and the second 3M double-sided tape is 0.25 mm to 1 mm, which is used to increase the reliability of the connection between the first flexible substrate 421 and the first shell 1, the second flexible substrate 521 and the second shell 2.

[0045] More specifically, the first electrode sheet 42 is a square patch with a side length of 1 cm to 2 cm, and the second electrode sheet 52 is a square patch with a side length of 1 cm to 2 cm, which are used to conduct electricity and thus form an electric field.

[0046] When in use, a direct current is generated by the constant current source circuit system and supplied to the first electrode sheet 42 and the second electrode sheet 52, so that a directional electric field is generated on the human body, and the gaps in the cornea and sclera are increased through electric field stimulation, thereby guiding the drug to penetrate into the deep part of the eye in a directional manner.

[0047] However, the long-term use of direct current will increase the Joule heat at the action position of the first electrode sheet 42 and the second electrode sheet 52, causing the pH value change caused by the electrochemical reaction to slow down the drug introduction efficiency, and in severe cases, it will also cause skin burns. Therefore, a first conductive hydrogel 41 is arranged on the side of the first electrode sheet 42, and a second conductive hydrogel 51 is arranged on the side of the second electrode sheet 52. The first conductive hydrogel 41 and the second conductive hydrogel 51 are used as ion introduction media to act on the human body, which can minimize the Joule heat generated by the first electrode sheet 42 and the second electrode sheet 52 on the skin, effectively buffer the pH value change caused by the electrochemical reaction, and absorb the heating caused by the electrode overpotential, thereby minimizing eye tissue damage and enhancing intraocular macromolecular delivery.

[0048] More specifically, the first conductive hydrogel 41 is a rectangular patch with a side length of 3×15 cm, and the second conductive hydrogel 51 is a rectangular patch with a side length of 3×15 cm, which are used to completely cover the eyes.

[0049] Specifically, one end of the second wire 523 is connected to the second electrode sheet 52, and the other end of the second wire 523 is connected to the negative interface terminal of the integrated circuit board. One end of the first wire 422 is connected to the first electrode sheet 42, and the other end of the first wire 422 is connected to the positive interface terminal of the integrated circuit board. In this connection state, the first electrode sheet 42 is used as a positive electrode, and the second electrode sheet 52 is used as a negative electrode. When powered on, an electric field perpendicular to the eye is formed between the first electrode sheet 42 and the second electrode sheet 52. Under the action of the electric field, the gap between the cornea and sclera changes to form a water channel with a fixed direction. The drug follows the water channel into the deep of the eye, realizing directional depth transport, while improving the drug delivery efficiency and accuracy.

[0050] As a further optimization scheme of the device, in order to improve the utilization rate of the device, a second treatment component for achieving the effect of aerosol drug delivery is also installed on the device.

[0051] like Figure 2 As shown, the second treatment component is arranged on the third shell 7 and the second shell 2. During use, the third shell 7 is used to replace the first shell 1, and other basic structures and connection relationships are the same.

[0052] The third shell 7 includes a frame and a lens arranged on the frame. Specifically, the lens can be made of a medical transparent material.

[0053] Among them, a third hydrogel patch 8 is arranged on one side of the frame close to the second shell 2. The third hydrogel patch 8 is frame-shaped, and its structure matches the frame.

[0054] When in use, a sealed environment is formed between the third hydrogel patch 8 and the human face to gather the mist medicine in front of the eyes. The third hydrogel patch 8 includes a third conductive hydrogel and a third electrode sheet, which are formed in a stacked structure, and the third electrode sheet is closely attached to the frame.

[0055] Specifically, the third electrode sheet includes a third flexible substrate, a third wire and a third electrode sheet. The third flexible substrate is printed with the third wire and the third electrode sheet. The two ends of the third wire are electrically connected to the third electrode sheet and the positive interface terminal of the constant current source circuit system respectively. A third 3M double-sided tape is provided on one side of the third flexible substrate, and the third 3M double-sided tape is used to achieve connection with the frame.

[0056] The negative interface terminal of the constant current source circuit system is electrically connected to the second electrode sheet 52, and the positive interface terminal is electrically connected to the third electrode sheet. After the constant current source circuit system supplies power, an electric field with a fixed direction is formed between the second electrode sheet 52 and the positive interface terminal.

[0057] Specifically, as a further specific implementation scheme of this embodiment, specifically, the thickness of the third 3M double-sided tape is 0.25 mm to 1 mm, which is used to increase the reliability of the connection between the third 3M double-sided tape and the frame.

[0058] The second treatment component also includes a nebulizer 6, a nebulizer catheter and a nebulizer catheter interface. The nebulizer catheter interface is opened on the third shell 7 and passes through the concave surface of the third shell 7. One end of the nebulizer catheter is detachably connected to the nebulizer catheter interface, and the other end of the nebulizer catheter is detachably connected to the nebulizer 6.

[0059] As a further specific implementation scheme of this embodiment, specifically, the nebulizer catheter is a soft transparent tube, and a conventional medical catheter can be used.

[0060] When in use, one end of the nebulizer catheter is connected to the nebulizer catheter interface, and the other end of the nebulizer catheter is connected to the nebulizer 6. By connecting the nebulizer 6, the atomized medicine is applied to the patient's eyes. The medicine liquid is atomized by the nebulizer 6, and then sent into the eyes through the nebulizer catheter and the nebulizer catheter interface. A direct current is generated by the constant current source circuit system and supplied to the third electrode sheet and the second electrode sheet 52, so that a directional electric field is generated on the human body. The gap between the cornea and sclera is increased by electric field stimulation, and the medicine is guided to penetrate into the deep of the eye in a directional manner.

[0061] As a further specific implementation of this embodiment, specifically, the first conductive hydrogel 41, the second conductive hydrogel 51 and the third conductive hydrogel all use a polyethylene glycol PEG hydrogel matrix. The polyethylene glycol PEG hydrogel matrix has a faster ability to respond to electric fields, and has better mechanical stability, thermal stability and chemical stability, good ductility and tensile properties, is not easy to be damaged and deformed, and has good biocompatibility, and is not easy to cause damage to the eyes when conducting electricity on the skin near the eyes.

[0062] As a further implementation scheme of this embodiment, specifically, the first flexible substrate 421, the second flexible substrate 521 and the third flexible substrate are made of polyimide film, polypropylene film, polyvinyl alcohol film or polyethylene terephthalate film, whose soft properties can better fit the hydrogel and the shell, achieving circuit insulation while functioning stably under high temperature and electric field.

[0063] As a further specific implementation scheme of this embodiment, specifically, the first electrode sheet 42, the second electrode sheet 52, the third electrode sheet, the negative electrode interface terminal and the positive electrode interface terminal of the constant current source circuit system are made of silver or silver chloride to prevent oxidation at high temperatures and improve service life.

[0064] As a further specific implementation scheme of this embodiment, specifically, the connecting member 3 includes a belt body and a connecting plate body, one end of the belt body is fixedly connected to the connecting plate body, and the other end is fixedly connected to the second shell 2, and a snap structure for realizing a detachable connection between the connecting plate body and the first shell 1 is respectively provided on the connecting plate body and the first shell 1, and the snap structure can be worn conveniently and quickly.

[0065] As a further specific implementation scheme of this embodiment, specifically, the belt body is a telescopic structure so as to be suitable for patients with different head circumference sizes. Specifically, the belt body is an elastic belt.

[0066] As a further specific implementation scheme of this embodiment, specifically, the snap-fit ​​structure includes a female buckle arranged on the first shell 1 and a sub-buckle arranged on the connecting plate body, and the sub-buckle matches the female buckle to achieve a detachable connection.

[0067] When in use, the patient can control the output current size and current duration by pressing the button switch. The output current range is 0.02mA-0.5mA, and the current action time range is 1min-60min.

[0068] It should be noted that the technical features or combinations of technical features described in the following embodiments should not be considered isolated. They can be combined with each other to achieve better technical effects. If necessary, the appropriate output current size and current action time can be selected according to the requirements of the clinician and in combination with the progression of the disease.

[0069] The device was used in actual treatment to compare the efficacy. The scheme and related results are as follows:

[0070] Experiment 1: Verification of the effect of iontophoresis scheme for eye drop administration

[0071] Testers: Recruiting testers, aged between 30-50, regardless of gender.

[0072] Test method: The experiment was divided into two groups, including 117 patients with uveitis, 75 in the experimental group and 42 in the control group. The experimental group used the device to administer the drug, while the control group received conventional medication. The patients were observed after one course of treatment.

[0073] The final result was that 51 people in the experimental group were cured, 19 people were improved, and 5 people were ineffective. The effective rate was 93.33%. In the control group, 9 people were cured, 20 people were improved, and 13 people were ineffective. The effective rate was 69.05%. The relevant experimental data are listed in Table 1:

[0074] Table 1 Experimental data of iontophoresis scheme for eye drops administration

[0075] Number of people cured Number of people who have improved Invalid number of people total Efficiency Experimental Group 51 19 5 75 93.33％ Control group 9 20 13 42 69.05％

[0076] Trial 2: Verification of the efficacy of ocular atomization drug delivery regimen

[0077] Testers: Recruiting testers, aged between 30-50, regardless of gender.

[0078] Test method: 120 patients with dry eye, 60 in the experimental group and 60 in the control group. The experimental group was given atomization medication, and the control group was given medication in the normal way. The number of effective people in the experimental group was 50, with an effective rate of 83.33%, and the number of effective people in the control group was 37, with an effective rate of 61.67%. The relevant experimental data are listed in Table 2 as follows:

[0079] Table 2 Experimental data of eye atomization drug delivery scheme

[0080] Effective number of people Invalid number of people total Efficiency Experimental Group 50 10 60 83.33％ Control group 37 23 60 61.67％

[0081] From the above two groups of test results, it can be seen that the iontophoresis drug delivery device provided by the present invention has high transdermal drug delivery efficiency and stability.

[0082] The above disclosure is only a preferred specific embodiment of the present invention, but the embodiments of the present invention are not limited thereto, and any changes that can be conceived by those skilled in the art should fall within the protection scope of the present invention.

Claims

1. An iontophoresis drug delivery device, characterized in that: include: A ring body, used to be worn on a patient's head, the ring body comprising a first shell (1), a second shell (2) and two connecting pieces (3) of identical structure, wherein opposite sides of the first shell (1) and the second shell (2) are arranged in an arc shape, and the two connecting pieces (3) are respectively located on both sides of the first shell (1) and are used to realize the connection between the first shell (1) and the second shell (2); A first treatment component, comprising a first hydrogel patch (4), a second hydrogel patch (5) and a constant current source circuit system, wherein the first hydrogel patch (4) is arranged on the concave surface of the first shell (1) and is used to be placed on the eye, the second hydrogel patch (5) is arranged on the concave surface of the second shell (2) and is used to be placed on the back of the head, and the constant current source circuit system is arranged on the second shell (2) and is electrically connected to the first hydrogel patch (4) and the second hydrogel patch (5) respectively; When the constant current source circuit system supplies power to the first hydrogel patch (4) and the second hydrogel patch (5), an electric field perpendicular to the eye is formed between the first hydrogel patch (4) and the second hydrogel patch (5). Under the action of the electric field, the gap between the cornea and sclera changes to form a water channel with a fixed direction, and the drug enters deep into the eye along the water channel.

2. The iontophoresis drug delivery device according to claim 1, characterized in that: The first hydrogel patch (4) comprises a first conductive hydrogel (41) and a first electrode sheet (42) arranged in a stacked structure, wherein the first electrode sheet (42) is arranged on the concave surface of the first shell (1) and is electrically connected to the constant current source circuit system; the first electrode sheet (42) comprises a first flexible substrate (421), a first wire (422) and a first electrode (423), wherein the first wire (422) and the first electrode (423) are printed on the first flexible substrate (421), and the two ends of the first wire (422) are electrically connected to the first electrode (423) and the constant current source circuit system respectively; a first 3M double-sided adhesive tape is arranged on one side of the first flexible substrate (421), and the first 3M double-sided adhesive tape is used to achieve connection with the first shell (1).

3. The iontophoresis drug delivery device according to claim 2, characterized in that: The second hydrogel patch (5) comprises a second conductive hydrogel (51) and a second electrode sheet (52) arranged in a stacked structure, the second electrode sheet (52) being closely attached to the concave surface of the second shell (2) and being electrically connected to the constant current source circuit system; the second electrode sheet (52) comprises a second flexible substrate (521), a second wire (523) and a second electrode sheet (522), the second wire (523) and the second electrode sheet (522) being printed on the second flexible substrate (521), the two ends of the second wire (523) being electrically connected to the second electrode sheet (522) and the constant current source circuit system respectively, and a second 3M double-sided adhesive tape is arranged on one side of the second flexible substrate (521), the second 3M double-sided adhesive tape being used to achieve connection with the second shell (2).

4. The iontophoresis drug delivery device according to claim 3, characterized in that: The first electrode sheet (42) and the second electrode sheet (522) are square in shape, with a side length of 1 cm to 2 cm.

5. The iontophoresis drug delivery device according to claim 3, characterized in that: The first conductive hydrogel (41) and the second conductive hydrogel (51) are rectangular in size of 3 cm×15 cm.

6. The iontophoresis drug delivery device according to claim 1, characterized in that: The first shell (1) is replaced by a third shell (7), the second treatment component is arranged on the third shell (7) and the second shell (2), the third shell (7) comprises a frame and a lens arranged on the frame, a third hydrogel patch (8) is arranged on a side of the frame close to the second shell (2), the third hydrogel patch (8) is frame-shaped, and the structure matches the frame; the constant current source circuit system is electrically connected to the third hydrogel patch (8) and the second hydrogel patch (5) respectively, when the constant current source circuit system supplies power to the third hydrogel patch (8) and the second hydrogel patch (5), an electric field perpendicular to the eye is formed between the third hydrogel patch (8) and the second hydrogel patch (5), under the action of the electric field, the gap between the cornea and sclera changes to form a water channel with a fixed direction, and the drug enters the deep of the eye along the water channel.

7. The iontophoresis drug delivery device according to claim 6, characterized in that: The third hydrogel patch (8) comprises a third conductive hydrogel and a third electrode sheet, the third conductive hydrogel and the third electrode sheet are composed of a stacked structure, the third electrode sheet is arranged on a frame and is frame-shaped, the third electrode sheet comprises a third flexible substrate, a third wire and a third electrode sheet, the third flexible substrate is printed with the third wire and the third electrode sheet, the two ends of the third wire are respectively electrically connected to the third electrode sheet and the positive interface terminal of the constant current source circuit system, and a third 3M double-sided tape is arranged on one side of the third flexible substrate, and the third 3M double-sided tape is used to achieve connection with the frame.

8. The iontophoresis drug delivery device according to claim 7, characterized in that: The second treatment component further comprises: a nebulizer catheter interface, a nebulizer (6) and a nebulizer catheter, wherein the nebulizer catheter interface is provided on the third shell (7) and passes through the concave surface of the third shell (7), one end of the nebulizer catheter is detachably connected to the nebulizer catheter interface, and the other end of the nebulizer catheter is detachably connected to the nebulizer (6).

Images